If you thought our angle on this company was interesting, you may want to check out our idea room, The Value Lab . We focus on long-only value ideas of interest to us, where we try to find international mispriced equities and target a portfolio yield of about 4% . We've done really well for ourselves over the last 5 years, but it took getting our hands dirty in international markets. If you are a value-investor, serious about protecting your wealth, our gang could help broaden your horizons and give some in ...

Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks. There is high visibility into the company's near-term baseline growth, with potential upside to revenue and earnings from "new product cycles and pipeline optionality," according to Goldman Sachs. Analyst David Roman initiated coverage of LivaNova with a Buy rating and price target of $65. The LivaNova Thesis: LivaNova's earnings had been under pressure due to strategic shifts in the company's business and pipeline setbacks. Ro ...

Financial Performance - Net revenue increased by 9.6% on a constant-currency basis to $318.6 million[1,4] - Excluding the ACS segment wind down, net revenue increased 10.8% on a constant-currency basis[94,73] - The company is targeting $95 - $115 million of adjusted free cash flow for full-year 2024[11] - LTM adjusted free cash flow was $139.9 million with an LTM adjusted free cash flow conversion ratio of 79%[11] Segment Performance - Cardiopulmonary revenue increased 14.5% to $173.7 million, driven by strong demand for consumables and Essenz sales[80,81] - Neuromodulation revenue increased 7.8% to $142.9 million, with growth across all regions[83,84] - United States Cardiopulmonary revenue increased 29.7% to $64.9 million[77] - United States Neuromodulation revenue increased 7.3% to $111.7 million[77] Guidance - The company is raising full-year guidance for net revenue growth to 7-8% and net revenue growth, excluding ACS, to 9-10%[31] - The company is raising full-year guidance for adjusted diluted EPS to $3.10 - $3.20[31]

LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 17.72%. A quarter ago, it was expected that this medical technology company would post earnings of $0.45 per share when it actually produced earnings of $0.73, delivering a surprise of 62.22%. Over the last four quarters, ...

EXHIBIT 99.1 London, July 31, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. • Announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study on June 6, 2024. Following additional in-depth analyses of the data, intends to pursue U.S. Centers for Medicare and Medicaid Services coverage for VNS Therapy™ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its cha ...

| --- | --- | --- | --- | --- | |------------------------------|-------|-------|-------|-------| | | | | | | | Liva Nova First Quarter 2024 | | | | | | Earnings Update | | | | | | May 1, 2024 | | | | | Safe Harbor 2 forward-looking statements, which are made only as of the date of this material. 3 • Trademarks for LivaNova's Neuromodulation systems, the VNS Therapy™ System, the VITARIA™ System and LivaNova's proprietary pulse generator products: Model 102 (Pulse™), Model 102R (Pulse Duo™), Model 103 (Demipu ...

LivaNova (LIVN) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 62.22%. A quarter ago, it was expected that this medical technology company would post earnings of $0.79 per share when it actually produced earnings of $0.87, delivering a surprise of 10.13%.Over the last four quarters, ...

EXHIBIT 99.1 NEWS RELEASE LivaNova Reports First-Quarter 2024 Results London, May 1, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights (1) "In the first quarter, LivaNova achieved double-digit revenue and operating income growth in both the Cardiopulmonary and Neuromodulation segments," said Vladimir Ma ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its charter) England and Wales ................... 98-126815 ...